Emergent Biosolutions EBS Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's debt issuance cost amortization?
- Emergent Biosolutions (EBS) reported debt issuance cost amortization of $1.8M in Q1 2026.
- How has Emergent Biosolutions's debt issuance cost amortization changed year-over-year?
- Emergent Biosolutions's debt issuance cost amortization decreased by 21.7% year-over-year, from $2.3M to $1.8M.
- What is the long-term trend for Emergent Biosolutions's debt issuance cost amortization?
- Over 3 years (2021 to 2025), Emergent Biosolutions's debt issuance cost amortization has grown at a 33.7% compound annual growth rate (CAGR), from $4.1M to $9.8M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).